Zejula® (niraparib)
for Ovarian Cancer

Zejula (niraparib) is a PARP inhibitor used as maintenance treatment to prevent the recurrence of certain cancers, including ovarian, fallopian tube, or peritoneal cancer. It is given after chemotherapy if the cancer has responded. Zejula is used in patients with specific genetic markers, like an abnormal "BRCA" gene. Niraparib works by blocking the PARP protein, preventing DNA repair in cancer cells, leading to their death and slowing tumor growth.

Heart
Medication Guide Icon Medication Guide
TV Commercial Icon TV Commercial
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Ovarian Cancer